
# There's a life behind every test

#### COVID-19, Flu A and Flu B with one assay

The **BD Veritor™ Plus System** now allows more options on a single assay, allowing you to test for **COVID-19**, **Flu A and Flu B** with just one sample. With multiple testing modes and workflow efficiencies, the Analyzer is more versatile than ever.

One sample. Three reliable results.

















## Get more answers with every sample.

Test for **COVID-19\***, **Flu A** and **Flu B** with a single sample, using the 3-in-1 assay from the **BD Veritor™ Plus System**.



#### Simplifies the testing process

 May help reduce manual test processing errors with its easy operation and single-button functionality



#### Achieves reliable, rapid results

- Displays easy-to-read digital results for COVID-19 and Flu A+B in 15 minutes<sup>1</sup>:
  - "CoV2: +" for positive; "CoV2: -" for negative
  - » "FLU A: +" for positive; "FLU A: -" for negative
  - » "FLU B: +" for positive; "FLU B: -" for negative
- Provides clear, objective results by correcting for nonspecific binding and detecting positives not recognized by the unaided eye<sup>1</sup>



#### **Delivers workflow efficiency**

- Adapts easily to your workflow by offering 2 operational modes
  - Walk Away: the test device is inserted immediately into the Analyzer so staff can multitask while the sample incubates (15 minutes)
  - » Analyze Now: the test device is inserted after the incubation time is complete, allowing batches of samples to be tested (results in seconds)



#### Provides result traceability

 Captures or downloads the lot number, patient/ specimen ID, operator ID, and test records using the BD Veritor™ InfoWiFi module

**Reference: 1.** BD Veritor™ System for Rapid Detection of SARS-CoV-2 and Flu A+B. Package insert. 500051910 Becton, Dickinson and Company.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663

### Clinical performance vs RT-PCR<sup>1</sup>

	PPA	NPA	Results in
SARS-CoV-2	<b>86.7%</b> (95% CI, 75.8%-93.1%)	<b>99.5%</b> (95% CI, 97.4%-99.9%)	
Influenzα A	<b>82.7%</b> (95% CI, 74.9%-88.5%)	<b>97.5%</b> (95% CI, 95.7%-98.5%)	15
Influenza B	<b>80.7%</b> (95% CI, 70.3%-88.1%)	<b>98.2%</b> (95% CI, 95.7%-99.3%)	_

SARS-CoV-2, Flu A and Flu B results in 15 minutes

NPA=negative percent agreement; PPA=positive percent agreement.

\*A negative result does not rule out COVID-19 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. A negative result should be considered in the context of a patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. For additional information, please refer to the HCP fact sheet.

Ordering information	Cat no.	Qty
BD Veritor™ Plus System SARS-CoV-2 & Flu A+B kit	256088	30 tests
BD Veritor™ Plus Analyzer	256066	1 unit

\*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

#### BDVeritor.com

